The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; Bristol-Myers Squibb; Enzon; Genentech; Genomic Health; GlaxoSmithKline; ImClone Systems; Infinity; Mersana; Roche
J. E. Tepper
No relevant relationships to disclose
D. Niedzwiecki
No relevant relationships to disclose
D. Hollis
No relevant relationships to disclose
H. J. Mamon
No relevant relationships to disclose
R. Swanson
No relevant relationships to disclose
D. G. Haller
No relevant relationships to disclose
T. Dragovich
No relevant relationships to disclose
S. R. Alberts
No relevant relationships to disclose
G. A. Bjarnason
No relevant relationships to disclose
C. G. Willett
No relevant relationships to disclose
P. C. Enzinger
No relevant relationships to disclose
R. M. Goldberg
Consultant or Advisory Role - Genentech; Lilly
Research Funding - Abbott Laboratories; Amgen; Bayer; Bristol-Myers Squibb; Genentech; Sanofi
A. P. Venook
No relevant relationships to disclose
R. J. Mayer
No relevant relationships to disclose